Large Comprehensive Pharmaceutical Product Developer
DP Technology
Simulation R&D Platform Developer
On August 22, 2025, Huadong Medicine (000963.SZ)Huadong Medicine and DP Technology Announce Strategic Collaboration. The two parties will leverage DP Technology's cutting-edge solutions to accelerate Huadong Medicine's drug discovery process, enhance R&D efficiency and quality, and jointly advance the digital and intelligent transformation of the pharmaceutical industry.
It is reported that,DP Technology as a globalLeader in AI for Science, Hermite® is a next-generation drug computing platform developed by DP Technology, integrating artificial intelligence, physical modeling, and high-performance computing to provide a one-stop computational solution for preclinical drug discovery: including core functional modules such as protein structure prediction, drug-target binding mode prediction, hit compound screening, and lead compound optimization. Uni-FEP, as the core module of DP Technology's Hermite® drug computational design platform, incorporates free energy perturbation theory, molecular dynamics, enhanced sampling algorithms, and high-performance computing to efficiently evaluate protein-ligand binding affinity with chemical accuracy. It can not only be used to assess protein-ligand binding free energy but also be widely applied in scenarios such as ligand selectivity prediction for homologous proteins, protein mutation stability prediction, and improving ADME/T properties, offering a comprehensive solution for drug discovery. First-half 2025 financial report.Huadong Medicine Achieves Revenue of 21.675 Billion Yuan, a Year-on-Year Increase of 3.39%; Net Profit Attributable to Shareholders of 1.815 Billion Yuan, a Year-on-Year Increase of 7.01%.
Huadong Medicine (000963.SZ) has been deeply engaged in the medical aesthetics sector for nearly 10 years. Since 2018, it has continuously introduced high-quality medical aesthetic products from home and abroad through investment and acquisitions. To date, Huadong Medicine's global medical aesthetics business has acquired36 Non-invasive + Minimally Invasive Medical Aesthetics ProductsAmong them, 22 products have been launched in China and overseas, and 14 globally innovative products are under development. The product portfolio covers mainstream non-surgical medical beauty fields such as facial fillers, facial cleansing, and threading.
In 2013, Huadong Medicine Co., Ltd. introducedHyaluronic Acid from LG Corporation, South KoreaThe product Yiwan became one of the earlier companies in the industry to adopt the license-in model, achieving a single-product revenue of 600-700 million yuan in 2018-2019, and emerging as the top player in the highly competitive hyaluronic acid market.In 2018, the companyAcquisition of UK's Sinclair, and obtained the heavyweight product "Ellansé®" (also known as "Young Girl Needle"); On April 13, 2021, Ellansé® S-type was approved for marketing by the National Medical Products Administration; On January 3, 2023, Ellansé® M-type successfully completed the enrollment and clinical injection of the first subject in China's clinical trial; On March 23, 2023, Ellansé® M-type successfully completed the enrollment of all subjects in China's clinical trial.In 2019, the companyReached a cooperation agreement with U.S. R2 company and holds 26.6% shares.%, obtained the Asia-Pacific rights to R2 Company's Fo and F1/2 products. The R2 team possesses top-tier R&D capabilities, with its core member, Professor Anderson, having previously transferred his developed product CoolSculpting to Allergan for 16 billion yuan.In August 2020, Huadong Medicine Co., Ltd. andJetema, a listed company in South KoreaSign a strategic cooperation agreement to obtain itsExclusive Agency Rights for Botulinum Toxin Type A Products in ChinaJetema applied for the IND of its Type A botulinum toxin product in China in 2021, with an expected approval for market launch in 2024.In March 2021, the wholly-owned subsidiary Sinclair acquiredSpanish Medical Beauty Equipment Company HighTechThe main products already on the market include the Cooltech, Cooltech Define, and Crystile series for cryolipolysis, as well as the Primelase and Elysion series for laser hair removal.September 2021,The company has reached a cooperation with Belgian KiOmed., obtaining the exclusive license for its four globally innovative KiOmedine chitosan medical aesthetics products in the global region (excluding the United States) in the field of skin aesthetics, which is expected to further enhance the hyaluronic acid product portfolio.In February 2022, the wholly-owned subsidiary SinclairAcquisition of Medical Aesthetics Device Company VioraThe company's main listed products include the Reaction multi-frequency radiofrequency device, the V Series multi-energy source integrated (radiofrequency, intense pulsed light, laser) multifunctional operating platform, the EnerJet needle-free minimally invasive high-pressure jet device, and the Pristine "diamond microcrystal dermabrasion device," among others. The Reaction product has obtained Class III medical device registration in China and is expected to be quickly introduced to the market.In September 2022, a new high-end hyaluronic acid filler containing lidocaine from Sinclair, a wholly-owned subsidiaryMaiLi ExtremeThe first subject of the clinical trial in China has been successfully enrolled and received clinical injection at the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. The MaiLi hyaluronic acid product obtained the EU CE certification in June 2020 and was launched in the European market in the first half of 2021.On December 26, 2022, Sinclair, a wholly-owned subsidiary in the UK under Huadong Medicine Co., Ltd.Regenerative Medical Beauty Injectable Lanluma® Type V and Type XApproved by the Hainan Provincial Drug Administration for clinical urgent need as an imported medical device, it will be used by designated doctors in the Medical Cosmetology Department of Huahan (Hainan) Aesthetic Hospital, located in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. It is intended to increase the volume of facial and body depressions, particularly suitable for correcting skin depressions.It is reported that Lanluma® is currently the only product approved globally.Can be used for buttock and thigh augmentationRegenerative products. According to Huadong Medicine, Lanluma® comes in two different specifications: Type V and Type X. Type V is used for filling smaller areas such as the face, upper arms, neck, and décolleté triangle area, while Type X is used for larger areas like the buttocks. Its main component is poly-L-lactic acid (PLLA), which is also known as the "baby face needle" in China.On July 4, 2023, Huadong Medicine Co., Ltd., a wholly-owned subsidiary of Huadong Medicine, submittedLiraglutide Injection for Obesity or Overweight IndicationsThe marketing authorization application has been approved, with the trade name Lilupin®, in the specification of 3ml:18mg (prefilled injection pen + cartridge), making it the first company in China to gain approval for a "weight loss" indication in the GLP-1 inhibitor field.On October 17, 2023, Huadong Medicine's wholly-owned Hong Kong subsidiary signed an exclusive product licensing agreement with South Korea's ATGC Co., Ltd., Obtain ATGC's containingATGC-11 Injection of Botulinum Toxin Type AGlobal exclusive license (excluding India) in regions including China, the United States, Europe, and non-exclusive license in South Korea, encompassing all indications for medical aesthetics and therapeutic clinical development, registration, and commercialization rights.On November 14, 2023, Huadong Medicine and Chongqing Yuyan announced the signing of an exclusive distribution agreement for the injectable recombinant botulinum toxin type A YY001.Huadong Medicine Obtains Ownership of Chongqing YuyanRecombinant Botulinum Toxin Type A YY001Exclusive commercial rights in the medical aesthetics indications field in mainland China, Hong Kong Special Administrative Region, and Macao Special Administrative Region.It is reported that YY001 is the first recombinant Type A botulinum toxin product in China to be approved for clinical trials, and it is also the only recombinant Type A botulinum toxin product in the world currently in the clinical stage.
On February 20, 2024, Huadong Medicine Co., Ltd. issued an announcement,The listing application for ATGC-110, the Type A botulinum toxin under South Korea's ATGC company exclusively represented by the company, has been accepted by South Korea’s Ministry of Food and Drug Safety (MFDS).. It is reported that,ATGC-110 is a neuroregulatory substance independently developed by ATGC, with its active pharmaceutical ingredient being 150kDa Type A botulinum toxin, used to improve symptoms in adult patients.Moderate to Severe Glabellar Lines。
February 29, 2024Huadong MedicineMaiLi, Sodium Hyaluronate Injectable with Lidocaine from Sinclair, a wholly-owned subsidiary in the UK®Extreme Achieves Primary Endpoint in Clinical Trials in China, This clinical study mainly focuses on evaluating MaiLi®Extreme: Efficacy and Safety of Injection in the Supraperiosteal Plane and/or Subcutaneous Adipose Tissue of the Face for Correction of Mild to Moderate Chin Retrusion.
On March 11, 2024, HDM1005 Injection, submitted by Sinopharm Huadong Co., Ltd., a subsidiary of Huadong Medicine, received tacit approval for clinical trials., Indicated for weight management in overweight or obese populations and type 2 diabetes. It is reported that HDM1005 is a long-acting dual agonist of GLP-1R/GIPR peptide, which was officially submitted for clinical trial on December 23, 2023.
On April 3, 2024, the official website of the Center for Drug Evaluation of the National Medical Products Administration showed that the marketing application for semaglutide injection "Ji You Tai" submitted by Hangzhou Jiuyuan Gene, a subsidiary of Huadong Medicine, has been accepted., Indicated for type 2 diabetes. According to reports,NineSource Gene Submits"Ji You Tai"YesThe first semaglutide biosimilar in China.
On May 9, 2024, Xinkeli Aesthetics, a wholly-owned subsidiary of Huadong Medicine Co., Ltd.SinclairThe National Operation Conference of REACTION by Huadong Medicine and the Launch Event of Rui·Slimming Project Successfully Held at Conrad Hangzhou.It is reported that with the release of REACTION芮艾瑅's new body treatment head, the application scenarios of radiofrequency treatment have been extended from the face to the entire body, bringing new and personalized solutions to the field of body contouring.
On June 19, 2024, Sinclair, a wholly-owned subsidiary of Huadong Medicine, will host the launch event for the second generation of Ellansé Evanesce products themed "Scientific Haute Couture, Radiant Renewal" at the Shanghai Shangri-La Hotel.It is reported that,The second-generation new products of Yiyan Shi have three models: Zhenyan (large microspheres), Zhizhen (medium microspheres), and Jingyan (medium microspheres). Based on three different sizes of microspheres, they can achieve "high-end customization" effects in different dimensions, addressing the needs of users of different age groups from various dimensions.。
On July 14, 2024, KIO015, an injectable skin filler product under Sinclair, a wholly-owned subsidiary of Huadong Medicine in the UK, has submitted an application for EU CE certification.It is reported that the product is expected to obtain the EU CE certification in 2025, and is likely to become the world's first non-animal-derived chitosan medical aesthetics filler.
September 13, 2024,Huadong Medicine's Participating Company, Chongqing Yuyan Pharmaceutical Co., Ltd., Announces the Successful Completion of Phase III Clinical Study for Recombinant Botulinum Toxin Type A Injection YY001 in Treating Moderate to Severe Glabellar Lines.It is reported that YY001 is a product independently developed by Yuyan Pharmaceutical with global intellectual property rights, and Huadong Medicine has the exclusive commercial rights for medical aesthetics indications in mainland China, Hong Kong, and Macao.
September 11, 2024Huadong Medicine Issues External Announcement,WillInvestment of 202 million yuanExpansion of "Comprehensive Peptide API Workshop" at Phase II Plant of Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd.。It is reported that,After the completion of this project, it can achieve an annual production of250kg of Semaglutide API, 120kg of Liraglutide Injection API, 80kg of Degludec Insulin API.
September 24, 2024Under Huadong MedicineThe "Intense Pulsed Light and Radio Frequency Therapy Device" V20 has been officially approved by the National Medical Products Administration (NMPA).Registration Certificate No.: GJXZZJ20243090527.According to reports,V20 is asSinclair Wholly-Owned SubsidiaryVioraThe multi-functional medical aesthetics operation platform, which integrates radio frequency (RF) and intense pulsed light (IPL) energy sources, has obtained FDA approval in the United States and CE certification in the European Union.
On October 11, 2024, the clinical trial for the "weight management" indication of the semaglutide injection jointly submitted by Huadong Medicine's wholly-owned subsidiaries, Sinopharm Huadong and Hangzhou Jiangdong, was approved by the National Medical Products Administration.It is reported that,Huadong Medicine and Chongqing Paikin have completed the enrollment of all subjects in the Phase III clinical study for the "diabetes" indication of the semaglutide injection. The primary endpoint data is expected to be obtained in Q4 2024.On October 24, 2024, Huadong Medicine Co., Ltd. released its financial report for the first three quarters. The medical aesthetics sector achieved a revenue of 1.909 billion yuan in the first three quarters.An increase of 1.90% year-on-yearAmong them, overseas Sinclair achieved revenue of approximately 776 million RMB, a year-on-year decrease of 20.30%; domestic Xinkeli Aesthetics achieved operating income of 909 million RMB, a year-on-year increase of 10.31%.。November 15, 2024, Huadong MedicineAnnounced externally, the companySignificant progress has been made in the domestic clinical trials of its four medical beauty products.It is reported that,Ellansé® Yiyanshi® S-type has completed the enrollment of all subjects in the new indication clinical trial; Lanluma® V has completed the enrollment of all subjects in the clinical trial, initiating the multi-center registration clinical research phase in China; KIO021 has completed the discussion meeting on the research protocol, and the clinical trial in China has been successfully launched; MaiLi® Precise has completed the primary endpoint follow-up for all subjects in the clinical trial in China.
January 20, 2025"Cross-linked Sodium Hyaluronate Gel Injection with Lidocaine" distributed by Xinkeli Aesthetics Shanghai Company, a wholly-owned subsidiary of Huadong Medicine Co., Ltd.MaiLi®ExtremeOfficially approved by the National Medical Products Administration, Registration No.: GuoXieZhuJin 20253130026.It is reported that,MaiLi®ExtremeIt is the one with the highest concentration of hyaluronic acid and the strongest fullness capability among the four products. It can provide immediate filling and shaping effects and quickly improve chin retrusion after injection.
January 23, 2025,Huadong Medicine's wholly-owned subsidiary Xinkeli Aesthetics submitted an application for "The registration application for "Ellansé® Evolence® M-type Polycaprolactone Microsphere Facial Filler" has been officially accepted by the National Medical Products Administration.It is reported that,Yiyan Shi® M-Type, compared to the S-Type, can induce long-term collagen regeneration with more lasting effects, offering excellent filling performance and safety.
March 5, 2025, Huadong MedicineWholly-owned subsidiaryViora's Class III medical device "Optical RF Therapeutic Instrument" V30 registration application has been officially accepted by the National Medical Products Administration.It is reported that,V30 was developed by Viora, a wholly-owned subsidiary of Sinclair.Integrated RF, IPL, and Nd:YAG laser energy sourcesAn integrated multifunctional medical aesthetics operation platform, mainly used for skin tightening, hair removal, vascular and pigmented lesions, acne, etc.March 31, 2025Semaglutide Injection Submitted by Jiangdong Company, a Wholly-Owned Subsidiary of Huadong Medicine (China-US Huadong)The marketing authorization application for HDG1901 has been accepted, with the indication being "Type 2 Diabetes Mellitus."It is reported that,Semaglutide InjectionClinical trial application for the "Weight Management" indication was submitted onApproved on October 11, 2024.April 17, 2025Huadong Medicine's subsidiary Hangzhou Zhongmei Huadong independently developed the innovative oral small molecule GLP-1 receptor agonist HDM1002 tablets for "weight loss indications," and the first subject was enrolled and dosed in the Phase III clinical trial at Yueyang People's Hospital.It is reported that this study is a multi-center, randomized, double-blind, placebo parallel-controlledⅢPhase clinical study aimed to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adult subjects.
On July 22, 2025, the clinical trial application for HDM1010 tablets submitted by Sinopharm Huadong Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd., was officially approved by the U.S. FDA for the indication of weight management in overweight or obese populations.It is reported that, as of now,HDM1010 tablets have been approved for 2 indications.FDA Approval, Including Type 2 Diabetes andWeight Management for Overweight or Obese Populations。
